Mohty, M; Cavo, M; Fink, L; Gonzalez-McQuire, S; Leleu, H; Mateos, M-V; Raab, MS; ... Yong, K; + view all Mohty, M; Cavo, M; Fink, L; Gonzalez-McQuire, S; Leleu, H; Mateos, M-V; Raab, MS; Schoen, P; Yong, K; - view fewer (2019) Understanding mortality in multiple myeloma: Findings of a European retrospective chart review. European Journal of Haematology , 103 (2) pp. 107-115. 10.1111/ejh.13264.

Preview

Text Mohty_et_al-2019-European_Journal_of_Haematology.pdf - Published Version Download (412kB) | Preview

Abstract

Objectives This study aimed to provide real‐world data on the characteristics and treatment of patients with multiple myeloma (MM) at the time of death. Methods The study was a retrospective patient chart review across France, Germany, Italy, Spain and the UK during 2016, and included patients who had died in the 3 months before the index date. Results Data from 786 patients were reviewed. At the time of death, 37% of patients were receiving active treatment, 12% were in a treatment‐free interval and 51% were receiving only supportive care. Death before and during active first‐line treatment was not uncommon (6% and 24% of patients, respectively) but these deaths were often not solely due to disease progression; factors such as renal failure and infection frequently played a role (in 30% and 20% of patients at first‐line, respectively). Most deaths at later lines were due to progressive disease. Cox model results suggested that early deaths were associated with advanced disease stage, high‐risk cytogenetics and poor response and relapse profiles. Conclusions These real‐world data could be used to help develop strategies for improving survival in patients with MM and to support management tailored to the stage of disease.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as JSONXMLCSV

Downloads by country - last 12 months

Export as XMLCSVJSON

Archive Staff Only

View Item